Effect of vitamin D on improvement of left ventricular ejection fraction in patients with systolic heart failure

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190410043236N1

Enrollment

Registered

2019-07-08

Start date

2016-05-02

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Systolic Heart failure. Condition 2: Systolic Heart failure. IX Diseases of the circulatory system Left ventricular failure

Interventions

Intervention 1: Intervention group: Intervention group: A 50000 unit capsule of vitamin D, manufactured by Abidi company, is given weekly and at 50,000 units for 8 weeks. It should be noted that patie

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: Chronic heart failure with 20%=EF=45% (based on Framingham criteria, NYAH Class I, II, III) The level of 25 (OH) Vit D is less than 30 ngr / dl Age over 40 years

Exclusion criteria

Exclusion criteria: Hypercalcemia Osteomalacia Taking corticosteroid medication

Design outcomes

Primary

Measure	Time frame
Ejection Fraction. Timepoint: Before beginning the intervention with vitamin D and placebo and then 2 months after the intervention. Method of measurement: Echocardiography.;End Diastolic Volume. Timepoint: Before beginning the intervention with vitamin D and placebo and then 2 months after the intervention. Method of measurement: Echocardiography.;Heart Failure Class. Timepoint: Before beginning the intervention with vitamin D and placebo and then 2 months after the intervention. Method of measurement: Echocardiography.	—

Measure

Time frame

Ejection Fraction. Timepoint: Before beginning the intervention with vitamin D and placebo and then 2 months after the intervention. Method of measurement: Echocardiography.;End Diastolic Volume. Timepoint: Before beginning the intervention with vitamin D and placebo and then 2 months after the intervention. Method of measurement: Echocardiography.;Heart Failure Class. Timepoint: Before beginning the intervention with vitamin D and placebo and then 2 months after the intervention. Method of measurement: Echocardiography.

—

Secondary

Measure	Time frame
Vitamin D. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: High Performance Liquid Chromatography.;Albumin. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: Immunoassay.;Creatinine. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: Immunoassay.;Calcium. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: Ion Selected (Specific) Electrode.;Phosphor. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: Ion Selected (Specific) Electrode.	—

Measure

Time frame

Vitamin D. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: High Performance Liquid Chromatography.;Albumin. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: Immunoassay.;Creatinine. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: Immunoassay.;Calcium. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: Ion Selected (Specific) Electrode.;Phosphor. Timepoint: Before the intervention, then two months after the intervention with vitamin D and placebo. Method of measurement: Ion Selected (Specific) Electrode.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Reza Hassanzadeh Makuei

Zanjan University of Medical Sciences

makuei42@yahoo.com+98 24 3353 4019

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026